ReleaseWire Connect

Office Depot Inc (NYSE: ODP) 3.27 +0.06 (1.87%). Office Depot Inc. held on to its No. 1 ranking in the Keynote Mobile performance index for the week ending Dec. 23. Its site loaded successfully 100% of the time and in 3.31 seconds on average. The combination of the speedy homepage load time and the impressive 100% availability is what helped the retailer land the No. 1 ranking yet again this week, says Herman Ng, mobile performance evangelist at Keynote Systems Inc.

Thompson Creek Metals Company Inc (USA) (NYSE: TC) 4.22 +0.14 (3.43%) The company announced the closing of its previously announced offering of $350,000,000 aggregate principal amount of its 9.75% Senior Secured First Priority Notes due 2017 (Senior Secured Notes). The Senior Secured Notes offering closed on November 27, 2012. The Company intends to use the proceeds from the offering for general corporate purposes, including capital expenditures relating to the development of its Mt. Milligan copper-gold mine.

Facebook Inc (NASDAQ:FB) 25.91 -0.14 (-0.53%). Instagram users annoyed with new rules, carried out their threats to dump the popular photo-sharing app. The app acquired by Facebook Inc (NASDAQ:FB) earlier this year for $1 billion, has lost nearly a quarter of its daily active users owing to the debacle. The company changed its service terms last week to incorporate advertising. The new terms allowed the company to sell user photos for advertising and promotions “without any compensation to you.”

Facebook Inc. (NASDAQ: FB), the social networking giant, is down sharply in mid-day trading today, extending its losses from the previous trading sessions. FB is currently trading 1.46% lower at $25.67 on volume of 28.84 million, which is well below the daily average volume of 73.88 million. FB has fallen more than 4% in the last three trading sessions.

Apple Inc. (NASDAQ: AAPL), the maker of iPhones and iPad, is marginally lower in mid-day trading today, tracking losses in the broad market. At last check, AAPL was trading 0.60% lower at $511.95 on volume of 5.04 million, which is nearly a quarter of the daily average volume of 21.86 million.

Schweitzer-Mauduit International Inc. (NYSE: SWM), a multinational diversified producer of specialty papers, is marginally lower in mid-day trading today. At last check, SWM was trading 0.03% lower at $38.97 on volume of 36,094, which is nearly a quarter of the daily average volume of 148,082.

Vical Incorporated (NASDAQ: VICL), a researcher and developer of biopharmaceutical-based products based on DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases, is down sharply in mid-day trading today, extending its losses from the previous trading sessions.

Canadian Solar Inc. (NASDAQ: CSIQ), a designer, developer and manufacturer of solar wafers, cells and solar module products that convert sunlight into electricity for a variety of uses, is up sharply in mid-day trading today. CSIQ is gaining momentum after the company announced the completion of purchase of two solar projects totaling 24 MW (DC) from SunEdison Power Canada Inc. The company also has the ability to complete a purchase of two more utility-scale solar power projects in Ontario, and an option to acquire a fifth solar project at a later date, subject to certain contractual conditions.

AEternaZentaris Inc. (NASDAQ: AEZS), a late-stage drug development company specializing in oncology and endocrine therapy, is soaring in mid-day trading today after the company announced that it has been granted a Special Protocol Assessment (SPA) by the U.S. FDA for Phase 3 registration trial in endometrial cancer with AEZS-108. Juergen Engel, Ph. D., President and CEO of AEZS, said that he is pleased with the agreement with the FDA which provides the company with a clearly defined development and regulatory pathway for AEZS-108 in endometrial cancer.

Questcor Pharmaceuticals, Inc.(NASDAQ: QCOR) 27.78 -2.12 (-7.09%). Range 27.35 - 29.78. 52 week 17.25 - 58.91. Questcor Pharmaceuticals, Inc. (QCOR) plunged in trade amid reports that Blue Cross Blue Shield had denied coverage of its top-selling drug, Acthar.